Related Experiment Video
Updated: Mar 3, 2026
09:32
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
15.6K
Immunotherapy in advanced melanoma: a network meta-analysis.
1Department of Pathology, Eulji University Hospital, Eulji University School of Medicine, Daejeon, 35233, Republic of Korea.
Immunotherapy
|May 6, 2017
Summary
Immunotherapy significantly improves objective response rates (ORR) in melanoma patients compared to chemotherapy. This finding supports immunotherapy as a superior treatment option for unresectable or metastatic melanoma.
Area of Science:
- Medical Oncology
- Immunotherapy Research
- Clinical Trial Analysis
Background:
- Melanoma, a significant skin cancer, presents challenges in unresected or metastatic stages.
- Chemotherapy has historically been a treatment option, but with limited efficacy.
- Emerging immunotherapies offer new hope for improved patient outcomes.
Purpose of the Study:
- To compare the effectiveness of various immunotherapeutic agents against chemotherapy for melanoma.
- To evaluate the objective response rate (ORR) of different treatments in melanoma patients.
Main Methods:
- A Bayesian network meta-analysis was conducted.
- Data from 12 randomized controlled studies were synthesized.
- Objective response rate (ORR) was the primary endpoint for comparison.
Main Results:
- Immunotherapy demonstrated a higher ORR (0.224) than chemotherapy (0.108).
- In untreated patients, immunotherapy's ORR was 0.279, and in pretreated patients, it was 0.176.
- Specific immunotherapies like nivolumab/ipilimumab, pembrolizumab, and nivolumab showed significantly higher odds ratios for ORR compared to chemotherapy alone.
Conclusions:
- Various immunotherapies exhibit superior ORRs compared to chemotherapy for melanoma.
- Immunotherapy represents a more effective treatment strategy for unresectable or metastatic melanoma.
